Hydroxyurea

Long-Term Outcomes of Fixed Low versus Moderate Hydroxyurea Dosing in Sickle Cell Stroke Prevention: Insights from the SPRINT Cohort

A long-term follow-up of the SPRINT trial shows no significant difference in recurrent stroke or mortality rates between initial low and moderate fixed doses of hydroxyurea in sickle cell disease, emphasizing event clustering within the fir